Savant Capital LLC Buys 8,198 Shares of Bruker Co. (NASDAQ:BRKR)

Savant Capital LLC boosted its stake in Bruker Co. (NASDAQ:BRKR) by 44.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,440 shares of the medical research company’s stock after acquiring an additional 8,198 shares during the period. Savant Capital LLC’s holdings in Bruker were worth $1,550,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in BRKR. Sanctuary Advisors LLC bought a new stake in Bruker in the second quarter worth about $296,000. GAMMA Investing LLC raised its position in Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after acquiring an additional 388 shares during the period. CWM LLC raised its position in Bruker by 191.9% in the third quarter. CWM LLC now owns 13,942 shares of the medical research company’s stock worth $963,000 after acquiring an additional 9,165 shares during the period. Rheos Capital Works Inc. bought a new stake in Bruker in the third quarter worth about $3,453,000. Finally, Inspire Advisors LLC bought a new stake in Bruker in the third quarter worth about $226,000. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $51.15 on Friday. The company has a 50 day moving average of $57.73 and a 200 day moving average of $60.71. The stock has a market cap of $7.75 billion, a P/E ratio of 24.59, a P/E/G ratio of 3.81 and a beta of 1.16. Bruker Co. has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%. As a group, sell-side analysts forecast that Bruker Co. will post 2.4 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 100,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 28.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on BRKR. Wells Fargo & Company lowered their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Bank of America boosted their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Guggenheim reissued a “buy” rating on shares of Bruker in a research report on Friday, January 17th. TD Cowen lowered their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Finally, Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bruker currently has a consensus rating of “Moderate Buy” and an average price target of $74.09.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.